Health Care • Biotechnology: Pharmaceutical Preparations
$4.53 ▼ -0.16
(-3.41%)
MKT CAP: $177.0M • VOL: 284.7K
52W L $1 52W H $7
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
ANTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$38.1M | -$56.8M | -$69.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$35.2M | -$51.3M | -$64.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$29.8M | -$49.3M | -$53.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$29.8M | -$49.3M | -$53.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $19.9M | $21.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $53.1M | $81.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANTX.